Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JUNAID ARSHAD

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1831506898
CMS profile
2789879
Location
LAKEWOOD, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,322.71

72 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,322.71 72

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–72 of 72 matching records. This page contains 22 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JUNAID ARSHAD

NPI 1831506898 · CMS profile ID 2789879

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

LAKEWOOD, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–72 of 72 matching records. This page contains 22 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1831506898?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JUNAID ARSHAD, NPI 1831506898, CMS profile ID 2789879. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–72 of 72 matching records. This page contains 22 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1831506898?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JUNAID ARSHAD, NPI 1831506898, CMS profile ID 2789879. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–72 of 72 matching records. This page contains 22 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1831506898?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JUNAID ARSHAD, NPI 1831506898, CMS profile ID 2789879, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–72 of 72 matching records. This page contains 22 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1831506898?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

72 matching records · $1,322.71 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 72 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–72 of 72.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme Corporation $14.7703/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848320463 CMS
AbbVie Inc. $19.7103/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793922157 CMS
Daiichi Sankyo Inc. $12.8803/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836271923 CMS
TOLMAR Pharmaceuticals, Inc. $13.7503/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836507065 CMS
Novartis Pharmaceuticals Corporation $17.2202/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812592151 CMS
Karyopharm Therapeutics Inc. $20.4502/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845786309 CMS
GlaxoSmithKline, LLC. $17.4602/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803065453 CMS
Merck Sharp & Dohme Corporation $16.6502/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848561737 CMS
Incyte Corporation $22.0502/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835576211 CMS
E.R. Squibb & Sons, L.L.C. $17.4002/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783538237 CMS
Eisai Inc. $15.4902/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817824440 CMS
Astellas Pharma US Inc $22.2102/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821250327 CMS
JAZZ PHARMACEUTICALS INC. $23.7902/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845626093 CMS
Alexion Pharmaceuticals, Inc. $18.9401/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783129593 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.8201/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763301716 CMS
Bayer HealthCare Pharmaceuticals Inc. $20.7601/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789083411 CMS
Bayer HealthCare Pharmaceuticals Inc. $20.5101/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789173543 CMS
Incyte Corporation $22.6601/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835576205 CMS
AstraZeneca Pharmaceuticals LP $20.4401/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829829345 CMS
AstraZeneca Pharmaceuticals LP $18.4301/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829944003 CMS
Pharmacyclics LLC, An AbbVie Company $24.9101/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781007969 CMS
Dova Pharmaceuticals $19.0001/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849747297 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $277.90 10
PY2020 $650.95 29
PY2021 $1,322.71 72
PY2022 $1,611.98 3
PY2023 $144.11 3
PY2024 $13,592.48 19
PY2025 $14,888.29 13

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $689,901.63 38
PY2024 Principal investigator $234,714.34 9
PY2023 Principal investigator $17,620.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

38 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $32,259.14 12/31/2025 Non-covered Recipient Entity
University of Arizona Cancer Center-University of Arizona Cancer Center
A Phase 1,2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab MK-3475 and,or Chemotherapy in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1,PD-L1 Treatment KEYMAKER-U06# Substud No dispute reported 06/30/2026 1232925629
Principal investigator 1 Merck Sharp & Dohme LLC $30,998.08 12/31/2025 Non-covered Recipient Entity
University of Arizona Cancer Center-University of Arizona Cancer Center
A Phase 1,2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of Investigational Agents in Combination With Standard of Care Treatments as the Second-Line Treatment of Participants with Advanced,Metastatic Gastroesophageal Ade No dispute reported 06/30/2026 1232925831
Principal investigator 1 Merck Sharp & Dohme LLC $32,097.81 12/31/2025 Non-covered Recipient Entity
University of Arizona Cancer Center-University of Arizona Cancer Center
A Phase 1,2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab MK-3475 and Chemotherapy in Participants with 1L Locally Advanced Unresectable,Metastatic Gastroesophageal Adenocarcinoma Gastric Adenocarcinoma, Gastro No dispute reported 06/30/2026 1232926135
Principal investigator 1 Merck Sharp & Dohme LLC $120,712.27 12/31/2025 Non-covered Recipient Entity
University of Arizona Cancer Center-University of Arizona Cancer Center
A Phase 1,2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab MK-3475 and Chemotherapy in Participants with 1L Locally Advanced Unresectable,Metastatic Gastroesophageal Adenocarcinoma Gastric Adenocarcinoma, Gastro No dispute reported 06/30/2026 1232926137
Principal investigator 1 Coherus Oncology, Inc. $1,040.00 12/23/2025 Non-covered Recipient Entity
University of Arizona
CHS38802 No dispute reported 06/30/2026 1235253757
Principal investigator 1 Merck Sharp & Dohme LLC $46,674.00 11/05/2025 Non-covered Recipient Entity
University of Arizona Cancer Center-University of Arizona Cancer Center
A Phase 1,2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab MK-3475 and,or Chemotherapy in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1,PD-L1 Treatment KEYMAKER-U06# Substud No dispute reported 06/30/2026 1232925627
Principal investigator 1 Genentech, Inc. $780.00 11/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211669362
Principal investigator 1 Genentech, Inc. $195.00 11/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211669368
Principal investigator 1 Genentech, Inc. $975.00 11/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211669371
Principal investigator 1 Genentech, Inc. $910.00 11/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211669374
Principal investigator 1 Coherus Oncology, Inc. $1,040.00 10/29/2025 Non-covered Recipient Entity
University of Arizona
CHS38802 No dispute reported 06/30/2026 1235253747
Principal investigator 1 Coherus Oncology, Inc. $1,755.00 10/29/2025 Non-covered Recipient Entity
University of Arizona
CHS38802 No dispute reported 06/30/2026 1235253750
Principal investigator 1 Amgen Inc. $183,315.36 10/17/2025 Non-covered Recipient Entity
UNIVERSITY OF ARIZONA CANCER CENTER
Expanded Access use of IMDELLTRA in a 35-year-old patient who was diagnosed with DLL3+ pancreatic neuroendocrine carcinoma No dispute reported 06/30/2026 1246650194
Principal investigator 1 Genentech, Inc. $2,391.00 10/07/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211669335
Principal investigator 1 Genentech, Inc. $65.00 10/07/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211669343
Principal investigator 1 Genentech, Inc. $1,040.00 10/07/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211669354
Principal investigator 1 Genentech, Inc. $1,040.00 10/07/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211669357
Principal investigator 1 Coherus Oncology, Inc. $41,790.00 09/16/2025 Non-covered Recipient Entity
University of Arizona
CHS38802 No dispute reported 06/30/2026 1235253753
Principal investigator 1 Merck Sharp & Dohme LLC $1,107.99 08/31/2025 Non-covered Recipient Entity
University of Arizona Cancer Center-University of Arizona Cancer Center
A Phase 1,2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of Investigational Agents in Combination With Standard of Care Treatments as the Second-Line Treatment of Participants with Advanced,Metastatic Gastroesophageal Ade No dispute reported 06/30/2026 1232925833
Principal investigator 1 Genentech, Inc. $294.00 08/01/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211669317
Principal investigator 1 Genentech, Inc. $780.00 08/01/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211669320
Principal investigator 1 Genentech, Inc. $975.00 08/01/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211669328
Principal investigator 1 Genentech, Inc. $1,040.00 07/01/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211669324
Principal investigator 1 Merck Sharp & Dohme LLC $44,809.00 06/16/2025 Non-covered Recipient Entity
University of Arizona Cancer Center-University of Arizona Cancer Center
A Phase 1,2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of Investigational Agents in Combination With Standard of Care Treatments as the Second-Line Treatment of Participants with Advanced,Metastatic Gastroesophageal Ade No dispute reported 06/30/2026 1232925829
Principal investigator 1 Merck Sharp & Dohme LLC $44,809.00 06/16/2025 Non-covered Recipient Entity
University of Arizona Cancer Center-University of Arizona Cancer Center
A Phase 1,2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab MK-3475 and Chemotherapy in Participants with 1L Locally Advanced Unresectable,Metastatic Gastroesophageal Adenocarcinoma Gastric Adenocarcinoma, Gastro No dispute reported 06/30/2026 1232926133
Principal investigator 1 Genentech, Inc. $2,248.00 06/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211669276
Principal investigator 1 Genentech, Inc. $2,391.00 06/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211669287
Principal investigator 1 Genentech, Inc. $2,355.00 06/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211669290
Principal investigator 1 Genentech, Inc. $1,560.00 06/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211669300
Principal investigator 1 Genentech, Inc. $1,950.00 06/02/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211669285
Principal investigator 1 Genentech, Inc. $2,600.00 05/08/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211669292
Principal investigator 1 Genentech, Inc. $195.00 04/01/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211669279
Principal investigator 1 Genentech, Inc. $8,200.00 04/01/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211669282
Principal investigator 1 Genentech, Inc. $18,655.00 04/01/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211669296
Principal investigator 1 Genentech, Inc. $650.00 04/01/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211669305
Principal investigator 1 Genentech, Inc. $5,850.00 04/01/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211669309
Principal investigator 1 Genentech, Inc. $14,560.00 04/01/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211669313
Principal investigator 1 AstraZeneca Pharmaceuticals LP $35,794.98 01/03/2025 Non-covered Recipient Entity
UNIVERSITY OF ARIZONA COLLEGE OF NURSING
a phase 3 multi center,open label,sponsor blinded,randomized study of azd0901 monotherapy compared with investigator s choice of therapy in second or later line adult participants with advanced metastatic gastric or gastroesophageal junction adenocarcinoma expressing claudin18 2 No dispute reported 06/30/2026 1185553489